[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
Cohort studies currently available suggest that the most effective platelet inhibitors for the secondary prevention of ischaemic cerebrovascular accidents are acetylsalicylic acid and ticlopidine. Aspirin reduces the risk by 20%. It seems that moderate doses (100-300 mg/day) are sufficient and better tolerated. Ticlopidine would seem to be more effective than aspirin as it reduces the risk by more than 20% with respect to aspirin therapy. Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction. Nowadays, other anti-platelet molecules are under evaluation, one of which is Clopidogrel.
Rosa
A
A
Service de neurologie, CHU Amiens Nord.
Canaple
S
S
D001161:Arteriosclerosis / Q000150:complications; D001241:Aspirin / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D004176:Dipyridamole / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011322:Primary Prevention; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D013988:Ticlopidine; D001241:Aspirin
Prévention primaire et secondaire des accidents ischémiques cérébraux liés à l'anthérosclérose par les antiplaquettaires.